The company completed a clinical trial at nine centers across the U.S., Europe and Asia before it received FDA approval.

New research shows that inhibiting overactive LRRK2 enzymes could stabilize Parkinson's disease progression, with Stanford ...

Dr. Simrit Parmar, a Northwestern University-trained oncologist and research scientist, launched Cellenkos Inc., in 2016 to ...

A drug used for Parkinson's disease has been shown to be effective in reducing the symptoms of difficult to treat depression, ...

The results of experiments in mice models were "astounding," said biochemist Suzanne Pfeffer of Stanford University.

Currently dopamine replacement medications, like levodopa and dopamine agonists, are the primary treatment for Parkinson's ...

Parkinson's drug reduces symptoms in treatment-resistant depression, clinical trial finds by University of Oxford edited by Lisa Lock, reviewed by Robert Egan Editors' notes ...

When 64-year-old MBK Nair first noticed a subtle tremor in his right hand in 2020, he brushed it off as fatigue or muscle ...

Parkinson's disease is a neurogenerative disease that affects more than 1 million people in the U.S. While some cases are ...

Most Parkinson's symptoms stem from the loss or dysfunction of dopamine-producing neurons in a brain region involved in fine ...

The drug is Ambroxol. It’s been used for decades to treat respiratory ailments by thinning mucus and easing coughs. But now, ...